title: [Osteocalcin and hyperthyroidism].
abstract: Osteoporosis may be induced by hyperthyroidism through an increase of bone turnover, because bone resorption exceeds formation in this condition. Also therapy with 1-thyroxine, especially by TSH-suppressive doses, may induce a reduction in bone mineral content. Circulating osteocalcin (sBGP) significantly increases both in endogenous and exogenous hyperthyroxinemia and is considered a reliable non invasive marker of bone turnover. In this study an extra-increase of sBGP in hyperthyroid post-menopausal women towards pre-menopausal is reported, the persistence of high sBGP levels in patients affected by any type of hyperthyroidism after four months of therapy and a positive relationship with thyroid hormones (fT4). Therefore monitoring of this serum marker may be suggested also in patient chronically treated with 1-thyroxine to avoid, if possible, overzealous therapy.
authors.affiliation: I Divisione Medica, Ospedale Maggiore, Lodi, Milano.
authors.forename: C
authors.initials: C
authors.lastname: Pandolfi
authors.forename: G
authors.initials: G
authors.lastname: Montanari
authors.forename: F
authors.initials: F
authors.lastname: Mercantini
authors.forename: G
authors.initials: G
authors.lastname: Sbalzarini
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001842:Bone and Bones / Q000378:metabolism; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood*; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood*
chemical_list: D015415:Biomarkers; D015675:Osteocalcin
vernacular_title: Osteocalcina e ipertiroidismo.